ResearcherChinese University of Hong KongActive in the last 2 years

Landon Long Chan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1306-5896; OpenAlex author ID A5036253377, A5124011728. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 4

RAS-targeted therapies for pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2026.100414 ↗
Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohistone H2BG53D. Co-author DOI 10.1016/j.celrep.2025.116596 ↗
PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-24-0425 ↗
Risks and impacts of thromboembolism in patients with pancreatic cancer. Co-author DOI 10.12809/hkmj219788 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Stephen Lam Chan · 3 shared papers, 2023–2026 · strength 0.85
Tsz Tung Kwong · 2 shared papers, 2024–2026 · strength 0.66
- Paper RAS-targeted therapies for pancreatic cancer. DOI 10.1016/j.esmogo.2026.100414 ↗
- Paper PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer. DOI 10.1158/2767-9764.crc-24-0425 ↗
Ksh Chok · 1 shared paper, 2024 · strength 0.23
- Paper PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer. DOI 10.1158/2767-9764.crc-24-0425 ↗
Kui Ming Chan · 1 shared paper, 2025 · strength 0.21
- Paper Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohisto… DOI 10.1016/j.celrep.2025.116596 ↗
Xin Wang · 1 shared paper, 2025 · strength 0.21
- Paper Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohisto… DOI 10.1016/j.celrep.2025.116596 ↗
Yi Ching Esther Wan · 1 shared paper, 2025 · strength 0.21
- Paper Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohisto… DOI 10.1016/j.celrep.2025.116596 ↗
Tiantian Qin · 1 shared paper, 2025 · strength 0.21
- Paper Dual inhibition of FACT and RRM2 suppresses the progression of pancreatic ductal adenocarcinoma driven by the oncohisto… DOI 10.1016/j.celrep.2025.116596 ↗
Raymond S. Y. Tang · 1 shared paper, 2023 · strength 0.19
- Paper Risks and impacts of thromboembolism in patients with pancreatic cancer. DOI 10.12809/hkmj219788 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.